Tìm theo
CMLVAX100
Thuốc Gốc
Biotech
CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia. It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.
Cơ Chế Tác Dụng : CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia. It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial. CMLVAX100 is a BCR-ABL peptide vaccine designed to reduce persistent disease in patients with chronic myeloid leukemia (CML) whom have had stable disease during conventional therapy. Targeting the BCR-ABL breakpoint with vaccine based medicines is an important approach to those with detectable CML. Breakthrough has optimized the components of VAX100 to enhance its activity.
Chỉ Định : Investigated for use/treatment in leukemia (myeloid).
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB05164
... loading
... loading